DexCom Investor Day Maps G8, Coverage Expansion and Double-Digit Growth

What happened

DexCom held its 2026 Investor Day and outlined a long-range plan centered on the G8 sensor launch, expanded insurance coverage for CGM, international growth, and margin improvement. The plan builds on recent momentum: preliminary 2025 revenue of ~$4.66B (+16% YoY) and 2026 guidance for $5.16-5.25B (+11-13%), with gross margins targeted at 63-64%. Management is betting on the G8 upgrade cycle, deeper penetration into Type 2 non-insulin and OTC/wellness segments via Stelo, and manufacturing consolidation to sustain double-digit growth and expand margins. The near-term focus is on resolving the FDA warning letter, managing CMS competitive bidding risk from 2027, and demonstrating that GLP-1 adoption is complementary to CGM usage. While the outlook is upbeat, execution risks remain on margin expansion and regulatory milestones, and the stock still trades at a discount reflecting these overhangs.

Implication

The investor day details support the base case of $80 value over 6-18 months, as G8 and coverage expansion should sustain 11-13% growth and margin improvement. However, the bear case risks ($55) remain if pricing pressure or regulatory issues escalate. We maintain our 3.5 conviction and re-assessment window; add on dips or after confirmed margin execution.

Thesis delta

The investor day provides greater clarity on the product roadmap and growth levers, reinforcing the base case and marginally increasing confidence that Dexcom can achieve its 2026 targets. No fundamental shift in thesis; the risk-reward still hinges on margin execution and regulatory closure.